The Stemline Therapeutics Inc (STML) Price Target Raised to $40.00

The Stemline Therapeutics Inc (STML) Price Target Raised to $40.00

Several other equities analysts also recently issued reports on STML. Zacks Investment Research downgraded Stemline Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, January 18th. Jefferies Group LLC set a $16.00 price objective on Stemline Therapeutics and gave the company a “buy” rating in a research report on Friday, February 3rd. Cowen and Company reiterated a “buy” rating on shares of Stemline Therapeutics in a research report on Thursday, February 2nd. Ladenburg Thalmann Financial Services reiterated a “buy” rating on shares of Stemline Therapeutics in a research report on Monday, February 6th. Finally, HC Wainwright set a $34.00 price objective on Stemline Therapeutics and gave the company a “buy” rating in a research report on Monday, February 27th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $29.17.

Stemline Therapeutics Inc (NASDAQ:STML) had its price objective lifted by equities researchers at Wedbush from $33.00 to $40.00 in a research note issued on Thursday, May 11th. The brokerage currently has an “outperform” rating on the biopharmaceutical company’s stock. Wedbush’s price objective would indicate a potential upside of 403.14% from the company’s previous close.

Stemline Therapeutics (NASDAQ:STML) opened at 7.95 on Thursday. The company has a 50-day moving average of $8.41 and a 200 day moving average of $9.63. Stemline Therapeutics has a 52 week low of $5.50 and a 52 week high of $14.60. The firm’s market cap is $185.84 million.

Several large investors have recently added to or reduced their stakes in the stock. Ladenburg Thalmann Financial Services Inc. boosted its stake in Stemline Therapeutics by 810.6% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 12,694 shares of the biopharmaceutical company’s stock valued at $136,000 after buying an additional 11,300 shares during the period. Renaissance Technologies LLC boosted its stake in Stemline Therapeutics by 7.9% in the fourth quarter. Renaissance Technologies LLC now owns 65,500 shares of the biopharmaceutical company’s stock valued at $701,000 after buying an additional 4,800 shares during the period. Candriam Luxembourg S.C.A. purchased a new stake in Stemline Therapeutics during the third quarter valued at approximately $2,783,000. Baker BROS. Advisors LP purchased a new stake in Stemline Therapeutics during the third quarter valued at approximately $3,612,000. Finally, State Street Corp boosted its stake in Stemline Therapeutics by 9.2% in the fourth quarter. State Street Corp now owns 251,804 shares of the biopharmaceutical company’s stock valued at $2,694,000 after buying an additional 21,296 shares during the period. 37.76% of the stock is owned by institutional investors. Stemline Therapeutics Company Profile

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:STML”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Related posts

Leave a Comment